Pharsight

Drugs that contain Icosapent Ethyl

1. Vascepa patents expiration

VASCEPA's oppositions filed in EPO
VASCEPA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9700537 AMARIN PHARMS Composition for preventing the occurrence of cardiovascular event in multiple risk patient
May, 2027

(3 years from now)

US9198892 AMARIN PHARMS Composition and/or method for preventing onset and/or recurrence of cardiovascular events
Sep, 2027

(3 years from now)

US8293728 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8415335 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8546372 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8680144 AMARIN PHARMS Methods of treating mixed dyslipidemia
Feb, 2030

(6 years from now)

US8293727 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8518929 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8524698 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8314086 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8318715 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8367652 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8399446 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8431560 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8440650 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8377920 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8357677 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8426399 AMARIN PHARMS Methods of treating hypertriglyceridemia
Feb, 2030

(6 years from now)

US8709475 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8501225 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US10010517 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8617594 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8551521 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8563608 AMARIN PHARMS Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Apr, 2030

(6 years from now)

US11154526 AMARIN PHARMS Methods of treating mixed dyslipidemia
Apr, 2030

(6 years from now)

US8623406 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8617593 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US10792267 AMARIN PHARMS Methods of treating mixed dyslipidemia
Apr, 2030

(6 years from now)

US10842766 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US10881632 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US11103477 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US11213504 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8454994 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US11717504 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Apr, 2030

(6 years from now)

US8618166 AMARIN PHARMS Methods of treating mixed dyslipidemia
Apr, 2030

(6 years from now)

US8642077 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8298554 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8703185 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8691871 AMARIN PHARMS Methods of treating mixed dyslipidemia
Apr, 2030

(6 years from now)

US10265287 AMARIN PHARMS Methods of reducing triglycerides and LDL-C
Apr, 2030

(6 years from now)

US8445013 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8445003 AMARIN PHARMS Stable pharmaceutical composition and methods of using same
Apr, 2030

(6 years from now)

US8455472 AMARIN PHARMS Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Jun, 2030

(6 years from now)

US10842768 AMARIN PHARMS Compositions and methods for lowering triglycerides
Jun, 2030

(6 years from now)

US8710041 AMARIN PHARMS Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy
Jun, 2030

(6 years from now)

US8669245 AMARIN PHARMS Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
Jun, 2030

(6 years from now)

US8410086 AMARIN PHARMS Compositions and methods for lowering triglycerides
Jun, 2030

(6 years from now)

US10894028 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US9603826 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US9610272 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US9623001 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US9693984 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US9693985 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US9693986 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US9918954 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US10278935 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US10278937 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US10278936 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Jun, 2033

(9 years from now)

US10383840 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10555925 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10555924 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10568861 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10668042 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US10576054 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10792270 AMARIN PHARMS Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease
Jun, 2033

(9 years from now)

US10786478 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US11000499 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US11116742 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US11369582 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

US11298333 AMARIN PHARMS Methods of reducing the risk of cardiovascular events in a subject
Jun, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 13, 2022

Market Authorisation Date: 26 July, 2012

Treatment: Use of vascepa as an adjunct to statin therapy to reduce the occurrence of a cardiovascular event in an adult patient with hypercholesterolemia; Use of vascepa as an adjunct to statin therapy to reduc...

Dosage: CAPSULE;ORAL

How can I launch a generic of VASCEPA before it's drug patent expiration?
More Information on Dosage

VASCEPA family patents

Family Patents